Structured JSON API for this factor page: https://sharemaestro.com/factors/api/tickers/7a75f9c4-6c06-4196-b76a-3dca72c1f3c9/

MDXG

MiMedx Group Inc
Chart
4.30 USD
Latest Week 2026-07-17
HealthcareBiotechnologySMALL
Snapshot 2026-07-12 · 0.9w · Fresh
0.84
OS Score
82.0%
Value
95.0%
Quality
12.0%
Momentum
5/9
F-Score
0.883
QV
StrategiesValueQualityMomentumCompositeInteractionsFactor AnalysisTrendsFundamentals
Strategy Eligibility
6 of 23 passing
★
OS Composite
OS 0.840
↗
Trending Value
✗
◆
Quality × Value
QV 0.883
🏛
Cornerstone Value
✗
🌿
Cornerstone Growth
✗
💎
Deep Value
✗
◇
VC2 Cheapest
✗
📐
EBITDA/EV
12.2%
◐
Veiled Value
✗
▣
Piotroski Bargains
✗
🔬
Quality Compounders
✗
📈
Consistent Earners
✗
🌱
GARP
Rev +11%
🔄
Shareholder Yield
✗
💰
High Yield
✗
🚀
Momentum Leaders
✗
◉
Market Leaders
✗
◎
Tiny Titans
✗
🔍
Small Cap Value
Val 82%
🛡
Low Volatility
✗
🏷
Sector Cheapest
✗
🧠
Capital Allocators
CAQ 0.91
⚡
Risk-Adj Momentum
✗
V
Value Analysis
Cheapness relative to fundamentals
82.0%ile
P/E
19.9×
P/S
1.6×
P/B
2.5×
E/P
0.0936
FCF Yield
0.161
EBITDA/EV
0.122
SH Yield
0.004
Relative Strength Across Value Dimensions
Multiples & Yields — Decomposition
VC1 (5-Factor)
26.00000000
/100 — 1=cheapest
VC2 (Trending Value)
32.00000000
/100
VC3 (Buyback)
33.00000000
/100
FCF yield of 16.1% is strong — the business generates significant free cash relative to price.
Q
Quality Analysis
Profitability, efficiency, balance sheet & earnings quality
95.0%ile
ROE
0.126
ROA
0.099
Net Margin
0.079
Op Margin
0.113
GPA
1.022
D/E
0.27
Current
5.39
F-Score
5/9
Quality Radar — Relative Strength
Profitability & Leverage Breakdown
Rev Growth
0.105
Earn Growth
-0.236
Stability
1.023
lower=better
Accruals
-0.129
lower=better
5yr Consist
No
Conservative balance sheet with D/E of 0.27.
M
Momentum & Risk
Price trend, volatility regime, risk-adjusted returns
12.0%ile
6M Return
-32.6%
12M Return
-38.3%
12-1 Mom
-45.9%
Risk-Adj
-1.32
Vol 252d
34.7%
Vol 60d
80.1%
↑ Expanding
Max DD 12M
-55.4%
Return Comparison — 6M / 12M / 12-1
Volatility Regime — 60d vs 252d
12-1 momentum of -46% signals a downtrend — price is moving against you. Near-term vol (80%) is expanding vs long-term (35%) — risk is increasing.
OS
Composite & Factor Heatmap
All factors at a glance
0.84
Pillar Balance — Value / Quality / Momentum
Factor Heatmap — green=strong, red=weak
▦
Sector Context
Healthcare · 500 peers
Sector Value %ile
89.8%
Sector Quality %ile
94.6%
P/E z-score
-0.16
P/B z-score
-0.21
Sector Avg OS
63.1%
Ticker vs Sector Averages
Relative Valuation Z-Score
Top Sector Peers (By OS)
SymbolNameOSValueQualityMomentum
RIGL Rigel Pharmaceuticals Inc 99.0% 89.0% 93.0% 94.0%
FBIOP Fortress Biotech Inc Pref Series A 99.0% 98.0% 83.0% 95.0%
TBPH Theravance Biopharma Inc 99.0% 90.0% 99.0% 88.0%
IRWD Ironwood Pharmaceuticals Inc 99.0% 90.0% 91.0% 99.0%
FBIO Fortress Biotech Inc 99.0% 98.0% 85.0% 90.0%
CGEN Compugen 98.0% 89.0% 96.0% 85.0%
NUTX Nutex Health Inc 98.0% 89.0% 98.0% 86.0%
INVA Innoviva Inc 98.0% 94.0% 94.0% 75.0%
Factor Interactions
Value + Quality Intersection
Top-tier on both cheapness (82th) and quality (95th) — the O'Shaughnessy sweet spot, historically the strongest long-term combination.
Falling Knife
Weak momentum (12th) despite looking cheap (82th value). Wait for momentum to stabilise.
Volatility Expanding
60-day vol (80%) significantly exceeds 252-day (35%). Near-term risk is elevated.
⚖
Factor Analysis
Comprehensive factor intelligence — strengths, weaknesses & cross-factor profile
Value
B
67.2% avg (7 factors)
Quality
B
71.1% avg (8 factors)
Momentum
F
0.0% avg (4 factors)
Risk
C
58.8% avg (1 factors)
This stock sits in the O'Shaughnessy sweet spot — cheap AND high quality. Historically, this combination has generated the strongest long-term returns. Momentum is weak, suggesting the market isn't yet buying this thesis. Patience required.
▲ Top Strengths — highest scoring factors
▼ Key Weaknesses — lowest scoring factors
Score Trends6 snapshots
Factor Persistence6 snapshots
FactorCurrentStreakTrendSpark
OS Composite0.840—6—
Value %ile0.820—6—
Quality %ile0.950—6—
Momentum %ile0.120—6—
F-Score5.000—0—
Confidence0.951—6—
Volatility0.347—0—
Value Lens2021-07-13 → 2026-07-12
P/E Ratio
Earnings Yield
Value FactorsCheapness relative to fundamentals — lower multiples = cheaper
P/E Ratio
19.94
Earnings Yield (E/P)
0.0936
Price / Sales
1.57
Price / Book
2.52
Price / Cash Flow
8.67
FCF Yield
16.1%
EBITDA / EV
12.2%
Sales Yield (1/P·S)
0.8286
Shareholder Yield
Div + net buyback / mktcap
0.4%
Quality FactorsProfitability, efficiency, and balance sheet strength
Return on Equity
12.6%
Return on Assets
9.9%
Net Margin
7.9%
Operating Margin
11.3%
Gross Profit / Assets
Novy-Marx GPA
102.2%
Debt / Equity
0.27
Current Ratio
5.39
Accruals Ratio
(NI-OCF)/Assets — lower=better
-0.129
MomentumPrice trend strength over different horizons
6M Return
-32.6%
12M Return
-38.3%
12-1 Momentum
Jegadeesh-Titman (skip recent month)
-45.9%
Risk-Adjusted Momentum
Mom 12-1 ÷ Vol
-1.32
Growth & StabilityEarnings trajectory, consistency, and capital allocation
Revenue Growth (YoY)
10.5%
Earnings Growth (YoY)
-23.6%
Earnings Stability (CV)
Lower = more stable
1.023
5yr Consistent
EPS up every year for 5 years
No
Piotroski F-Score
5
Buyback Yield
0.4%
O'Shaughnessy CompositesValue Composites (WWOWS 4th Ed) — 1=cheapest, 100=most expensive
VC1 (5-factor)
P/E+P/S+P/B+P/CF+EBITDA/EV
26
VC2 (6-factor)
VC1 + Shareholder Yield — used for Trending Value
32
VC3 (6-factor)
VC1 + Buyback Yield — no dividend preference
33
Capital Allocation & AlphaAlpha within factors — quality of management decisions
Veiled Value
Expensive by P/B, cheap by everything else
No
Market Leader
Above-avg mcap+revenue, non-utility
No
All Stocks Universe
Market cap > $200M
Yes
Tiny Titan
Micro-cap, low P/S, positive momentum
No
Quarterly Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity
Annual Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity